Boyu Hu, MD (University of Utah Health), discusses the increased risk of transformation in follicular lymphoma and its impact on treatment effectiveness.
Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
When Chris Gorelik received news that his central nervous system lymphoma would leave him with months to live, he sought a second opinion and took a chance on a new treatment protocol — to give him a fighting chance to see his children grow up.
Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.
With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.
Stay informed with news, alerts and other resources.